"
Team:Bielefeld-Germany/Results/Unfinished
From 2010.igem.org
(New page: {{Bielefeld_MainMenu_2010}} ==Unfinished BioBricks== ===Mutated ''virG''=== This version of ''virG'' activates ''vir'' promotors in ''Escherichia coli'' without the ''rpoA''-gene from ''...) |
|||
| Line 5: | Line 5: | ||
===Mutated ''virG''=== | ===Mutated ''virG''=== | ||
This version of ''virG'' activates ''vir'' promotors in ''Escherichia coli'' without the ''rpoA''-gene from ''Agrobacterium tumefaciens''. For this reason the point mutations G56V and I77V are brought into the molecule (compare YC Jung ''et al.'', 2004). Because this BioBrick is synthesized by Mr. Gene, codon usage is optimized for ''E. coli'' and illegal restriction sites were removed. | This version of ''virG'' activates ''vir'' promotors in ''Escherichia coli'' without the ''rpoA''-gene from ''Agrobacterium tumefaciens''. For this reason the point mutations G56V and I77V are brought into the molecule (compare YC Jung ''et al.'', 2004). Because this BioBrick is synthesized by Mr. Gene, codon usage is optimized for ''E. coli'' and illegal restriction sites were removed. | ||
| + | |||
| + | ===''virA'' receptor=== | ||
| + | Actually we wanted to use the ''virA'' receptor already existing in the partsregistry (BBa_K238008). But due to some problems (compare results in BioBricks/tested) we decided to isolate the ''virA'' gene from ''A. tumefaciens'' C58 ourselves and bring it into a BioBrick compatible form. We removed an illegal ''PstI'' restriction site in the ''virA'' gene by site-directed mutagenesis. | ||
| + | |||
| + | ===''vir''-promotor=== | ||
| + | We wanted to use the ''vir''-promotor from the partsregistry (BBa_K238011) but the same problems occurred like with the use of the ''virA'' receptor from the partsregistry. So we also have to create a new ''vir''-promotor BioBrick. | ||
===Neomycin / kanamycin resistance=== | ===Neomycin / kanamycin resistance=== | ||
| Line 10: | Line 16: | ||
===BioBrick for ''virA''-screenings=== | ===BioBrick for ''virA''-screenings=== | ||
| - | This part contains our mutated ''virG'' BioBrick under the control of a constitutive promotor ( | + | This part contains our mutated ''virG'' BioBrick under the control of a constitutive promotor (BBa_J23110) and an antibiotic resistance (tetracyclin or neomycin) under the control of the ''virB'' promotor. The better the ''virA'' receptor recognizes a substance the stronger will the antibiotic resistance be expressed. |
===Mutated ''virA''=== | ===Mutated ''virA''=== | ||
Revision as of 11:06, 4 August 2010
Contents |
Unfinished BioBricks
Mutated virG
This version of virG activates vir promotors in Escherichia coli without the rpoA-gene from Agrobacterium tumefaciens. For this reason the point mutations G56V and I77V are brought into the molecule (compare YC Jung et al., 2004). Because this BioBrick is synthesized by Mr. Gene, codon usage is optimized for E. coli and illegal restriction sites were removed.
virA receptor
Actually we wanted to use the virA receptor already existing in the partsregistry (BBa_K238008). But due to some problems (compare results in BioBricks/tested) we decided to isolate the virA gene from A. tumefaciens C58 ourselves and bring it into a BioBrick compatible form. We removed an illegal PstI restriction site in the virA gene by site-directed mutagenesis.
vir-promotor
We wanted to use the vir-promotor from the partsregistry (BBa_K238011) but the same problems occurred like with the use of the virA receptor from the partsregistry. So we also have to create a new vir-promotor BioBrick.
Neomycin / kanamycin resistance
A neomycin / kanamycin resistance gene without promotor is isolated and brought into a BioBrick compatible form.
BioBrick for virA-screenings
This part contains our mutated virG BioBrick under the control of a constitutive promotor (BBa_J23110) and an antibiotic resistance (tetracyclin or neomycin) under the control of the virB promotor. The better the virA receptor recognizes a substance the stronger will the antibiotic resistance be expressed.
Mutated virA
The virA gene is mutated by error prone PCR and screened for several phenolic substances (e.g. capsaicin and homovanillic acid). The goal is to receive highly specific and sensitive mutated virA receptors by directed evolution.
Firefly luciferase
Bringing the firefly luciferase gene from Promega's pGL4 vector into a BioBrick compatible form as a sensitive reporter gene.
Reporter construct
The reporter construct is similar to the virA screening construct but instead of the antibiotic resistance it carries a reporter gene (e.g. GFP or luciferase). The amount of produced reporter shows the activity of the virA receptor.
Literature
YC Jung et al. (2004) Mutants of Agrobacterium tumefaciens virG Gene That Activate Transcription of vir Promoter in Escherichia coli, Current Microbiol 49:334-340.
